I
9.18
-0.12 (-1.29%)
| Penutupan Terdahulu | 9.30 |
| Buka | 9.30 |
| Jumlah Dagangan | 309,832 |
| Purata Dagangan (3B) | 360,286 |
| Modal Pasaran | 203,543,552 |
| Harga / Jualan (P/S) | 10.81 |
| Harga / Buku (P/B) | 5.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2025 - 31 Mar 2025 |
| Margin Operasi (TTM) | -304,535.72% |
| EPS Cair (TTM) | -2.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.20% |
| Nisbah Semasa (MRQ) | 3.14 |
| Aliran Tunai Operasi (OCF TTM) | -33.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.45 M |
| Pulangan Atas Aset (ROA TTM) | -55.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | INmune Bio Inc. | Menaik | Menaik |
AISkor Stockmoo
1.9
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.88 |
|
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 27.78% |
| % Dimiliki oleh Institusi | 27.69% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (Maxim Group, 226.80%) | Beli |
| Median | 26.50 (188.67%) | |
| Rendah | 23.00 (Scotiabank, 150.55%) | Beli |
| Purata | 26.50 (188.67%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 8.78 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Maxim Group | 13 Feb 2025 | 30.00 (226.80%) | Beli | 9.30 |
| Scotiabank | 11 Feb 2025 | 23.00 (150.54%) | Beli | 8.25 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Apr 2025 | Pengumuman | INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study |
| 27 Mar 2025 | Pengumuman | INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update |
| 24 Mar 2025 | Pengumuman | INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 |
| 12 Feb 2025 | Pengumuman | INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer |
| 10 Feb 2025 | Pengumuman | INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
| 28 Jan 2025 | Pengumuman | INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |